Addus HomeCare (NASDAQ:ADUS) Receives Outperform Rating from Macquarie

Addus HomeCare (NASDAQ:ADUSGet Free Report)‘s stock had its “outperform” rating reissued by stock analysts at Macquarie in a research note issued to investors on Monday, Benzinga reports. They currently have a $139.00 price target on the stock. Macquarie’s price target indicates a potential upside of 8.71% from the stock’s previous close.

Other equities analysts also recently issued reports about the company. Oppenheimer lifted their target price on Addus HomeCare from $140.00 to $145.00 and gave the company an “outperform” rating in a research report on Monday, September 23rd. StockNews.com downgraded Addus HomeCare from a “strong-buy” rating to a “buy” rating in a research report on Sunday, July 7th. KeyCorp started coverage on Addus HomeCare in a research report on Friday, October 11th. They set an “overweight” rating and a $150.00 target price on the stock. Royal Bank of Canada reiterated an “outperform” rating and set a $141.00 target price on shares of Addus HomeCare in a research report on Tuesday, September 3rd. Finally, Stephens reissued an “overweight” rating and set a $138.00 price target on shares of Addus HomeCare in a report on Tuesday, August 6th. One equities research analyst has rated the stock with a sell rating, eight have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Addus HomeCare has a consensus rating of “Moderate Buy” and a consensus price target of $131.38.

Get Our Latest Analysis on ADUS

Addus HomeCare Trading Up 1.3 %

ADUS traded up $1.59 during trading on Monday, hitting $127.86. 89,382 shares of the company’s stock traded hands, compared to its average volume of 130,574. The company’s 50 day simple moving average is $130.02 and its two-hundred day simple moving average is $120.43. Addus HomeCare has a 12-month low of $81.51 and a 12-month high of $136.12. The stock has a market capitalization of $2.31 billion, a price-to-earnings ratio of 30.11, a PEG ratio of 2.25 and a beta of 1.04.

Addus HomeCare (NASDAQ:ADUSGet Free Report) last released its quarterly earnings results on Monday, August 5th. The company reported $1.35 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.21 by $0.14. The firm had revenue of $286.90 million for the quarter, compared to the consensus estimate of $284.90 million. Addus HomeCare had a return on equity of 9.81% and a net margin of 6.18%. The company’s revenue for the quarter was up 10.4% on a year-over-year basis. During the same period last year, the business posted $0.94 EPS. On average, equities analysts expect that Addus HomeCare will post 4.57 EPS for the current year.

Insider Buying and Selling at Addus HomeCare

In other Addus HomeCare news, Director Esteban Lopez sold 500 shares of the business’s stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $127.50, for a total transaction of $63,750.00. Following the completion of the transaction, the director now owns 3,366 shares in the company, valued at $429,165. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In related news, Director Esteban Lopez sold 500 shares of the business’s stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $127.50, for a total value of $63,750.00. Following the completion of the sale, the director now owns 3,366 shares in the company, valued at approximately $429,165. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Michael D. Wattenbarger sold 21,917 shares of the business’s stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $133.29, for a total value of $2,921,316.93. Following the completion of the sale, the executive vice president now owns 7,215 shares of the company’s stock, valued at $961,687.35. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 22,917 shares of company stock worth $3,050,082 over the last 90 days. Company insiders own 4.60% of the company’s stock.

Hedge Funds Weigh In On Addus HomeCare

Large investors have recently bought and sold shares of the business. UMB Bank n.a. raised its stake in Addus HomeCare by 64.2% in the second quarter. UMB Bank n.a. now owns 225 shares of the company’s stock worth $26,000 after buying an additional 88 shares in the last quarter. Quest Partners LLC acquired a new position in shares of Addus HomeCare during the second quarter worth $31,000. Farther Finance Advisors LLC increased its position in shares of Addus HomeCare by 9,150.0% during the third quarter. Farther Finance Advisors LLC now owns 370 shares of the company’s stock worth $49,000 after purchasing an additional 366 shares in the last quarter. Innealta Capital LLC acquired a new position in shares of Addus HomeCare during the second quarter worth $44,000. Finally, EntryPoint Capital LLC acquired a new position in shares of Addus HomeCare during the first quarter worth $44,000. Institutional investors own 95.35% of the company’s stock.

Addus HomeCare Company Profile

(Get Free Report)

Addus HomeCare Corporation, together with its subsidiaries, provides personal care services to elderly, chronically ill, disabled persons, and individuals who are at risk of hospitalization or institutionalization in the United States. The company operates through three segments: Personal Care, Hospice, and Home Health.

Further Reading

Analyst Recommendations for Addus HomeCare (NASDAQ:ADUS)

Receive News & Ratings for Addus HomeCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Addus HomeCare and related companies with MarketBeat.com's FREE daily email newsletter.